Broadcom
AVGO
Taiwan Semiconductor
TSM
Tesla
TSLA
ASML Holding
ASML
Qualcomm
QCOM
US Stock MarketDetailed Quotes
LRMR Larimar Therapeutics
- 6.170
- +0.060+0.98%
Close Dec 13 16:00 ET
- 6.170
- 0.0000.00%
Post 19:59 ET
393.69MMarket Cap-5.37P/E (TTM)
6.307High6.010Low436.14KVolume6.200Open6.110Pre Close2.68MTurnover1.38%Turnover RatioLossP/E (Static)63.81MShares13.68052wk High1.98P/B195.08MFloat Cap3.79552wk Low--Dividend TTM31.62MShs Float664.320Historical High--Div YieldTTM4.85%Amplitude1.530Historical Low6.153Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Larimar Therapeutics Stock Forum
Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics announced that the FDA has selected its therapy, nomlabofusp, for the START pilot program. This program aims to accelerate the development of treatments for rare diseases. Nomlabofusp is a novel protein replacement therapy targeting the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria.
The selection...
⇒ $Larimar Therapeutics (LRMR.US)$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals (CTXR.US)$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics (HALO.US)$ $Bristol-Myers Squibb (BMY.US)$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
NEWS
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Larimar Therapeutics (Nasdaq: LRMR) announced that the FDA has removed the partial clinical hold on their nomlabofusp (CTI-1601) program, aimed at treating Friedreich’s Ataxia (FA). This decision followed the review of data from a recently completed Phase 2 dose exploration study, which included 25 mg and 50 mg cohorts. The study showed that nom...
$BiomX (PHGE.US)$ $Larimar Therapeutics (LRMR.US)$ $Clene (CLNN.US)$ $Glucotrack (GCTK.US)$ $Sonnet BioTherapeutic (SONN.US)$ $FibroBiologics (FBLG.US)$ $NS WIND DOWN CO INC (NSTGQ.US)$
📊⚡️📊
more insider buys
No comment yet